Topic Lung Cancer
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Explores Durvalumab Plus Ceralasertib in Immunotherapy-Resistant Lung Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0524Published: May 2024Expires: 4/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Durvalumab plus Ceralasertib , Lung CancerMedia:
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Explores Durvalumab Plus Ceralasertib in Immunotherapy-Resistant Lung Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0524Published: May 2024Expires: 4/30/2026Sources: Oncology TimesDetailsRequired Passing Score: 4/5 (80%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Durvalumab plus Ceralasertib , Lung CancerMedia: